SEC 13F Intelligence

Managers / Q4 2020 · view latest →

KNOTT DAVID M

CIK 0000808722

Reported Value
$221M
Q4 2020
Positions
145
Filings on Record
12
2019–present window
Filed
Feb 12, 2021
original filing

Summary

Knott David M reported $221M in U.S.-listed holdings across 145 positions for Q4 2020.

Its largest position, LGND, represents 10.7% of the portfolio.

Compared with Q3 2020, the fund opened 20 new positions and exited 10.

Portfolio Metrics

Turnover
+11.3%
vs prior filed quarter
Top-10 Concentration
+54.7%
share of reported value
Largest Position
+10.7%
Ligand Pharmaceuticals Incorporated
New / Exited
20 / 10
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’18: $213MQ4 ’18Q1 ’19: $251MQ2 ’19: $237MQ2 ’19Q3 ’19: $238MQ4 ’19: $247MQ4 ’19Q1 ’20: $158MQ2 ’20: $183MQ2 ’20Q3 ’20: $170MQ4 ’20: $221MQ4 ’20Q1 ’21: $234MQ2 ’21: $281MQ2 ’21Q3 ’21: $275Mfilingsflow.com

Portfolio Composition

By security type
Common Stock: 69.5%Other: 15.7%Ltd Part: 7.4%MLP: 5.5%Unit: 1.2%Other: 0.8%
  • Common Stock · 69.5% · $153M
  • Other · 15.7% · $35M
  • Ltd Part · 7.4% · $16M
  • MLP · 5.5% · $12M
  • Unit · 1.2% · $3M
  • Other · 0.8% · $2M

Quarter-over-Quarter Changes full breakdown →

vs Q3 2020 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
Danimer Scientific, Inc.NEW+500.0K500.0K+$12M$12M
FSKFS KKR Capital Corp.NEW+395.2K395.2K+$7M$7M
iPath Series B S&P 500 VIX Short-Term FutNEW+200.0K200.0K+$3M$3M
EBCEastern Bankshares IncNEW+200.0K200.0K+$3M$3M
CAP/UCapitol Investment Corp. VNEW+250.0K250.0K+$3M$3M
Horizon Aquistion CorporationNEW+210.1K210.1K+$2M$2M
Reinvent Technology PartnersNEW+176.2K176.2K+$2M$2M
CNSTConstellation Phamaceuticals, Inc.NEW+33.0K33.0K+$950,000$950,000

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q4 2020

48 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1LGNDLigand Pharmaceuticals Incorporatedhistory →Common11.08%$24M246.2K
2UPLDEURUpland Software, Inc.history →Common8.44%$19M406.5K
3FTAIEURFortress Trans & Infrastructure Inv. LLChistory →Common7.43%$16M700.0K
4APOEURApollo Global Management, Inc.history →Common6.65%$15M300.0K
5Danimer Scientific, Inc.Common5.32%$12M500.0K
6GOOGAlphabet Inc-Cl Chistory →Common4.44%$10M5.6K
7Calumet Specialty Products Partners, LPCommon3.72%$8M2.63M
8MDWTUSDMidwest Holdings Inc.history →Common3.49%$8M143.6K
9FSKFS KKR Capital Corp.history →Common2.62%$6M350.0K
10PFEPfizer Inc.history →Common2.00%$4M119.9K
11LKQ1LKQ Corporationhistory →Common1.91%$4M120.0K
12KKRKKR & Co. Inc.history →Common1.83%$4M100.0K
13GILDGilead Sciences, Inc.history →Common1.71%$4M64.8K
14Kennedy-Wilson Holdings, Inc.Common1.70%$4M210.0K
15CLDNEUREiger BioPharmaceuticals, Inc.history →Common1.64%$4M295.0K
16iPath Series B S&P 500 VIX Short-Term FutCommon1.52%$3M200.0K
17BMYBristol-Myers Squibb Companyhistory →Common1.47%$3M52.4K
18Horizon Therapeutics Public Ltd. CompanyCommon1.41%$3M42.6K
19EBCEastern Bankshares Inchistory →Common1.40%$3M190.0K
20XENEXenon Pharmaceuticals Inc.history →Common1.39%$3M200.0K
21ABBVAbbVie Inc.history →Common1.35%$3M27.8K
22KDMNKadmon Holdings, Inc.history →Common1.32%$3M702.0K
23TGTXTG Therapeutics Inc.history →Common1.20%$3M50.8K
24CAP/UCapitol Investment Corp. Vhistory →Common1.17%$3M250.0K
25TREURTrillium Therapeutics Inc.history →Common1.16%$3M174.7K
26AUPHAurinia Pharmaceuticals Inc.history →Common1.11%$2M177.5K
27ZGNXEURZogenix, Inc.history →Common1.02%$2M112.7K
28MPLXMPLX LPCommon0.98%$2M100.0K
29Horizon Aquistion CorporationCommon0.95%$2M210.1K
30Reinvent Technology PartnersCommon0.92%$2M176.2K
31JPMJP Morgan ChaseCommon0.82%$2M14.3K
32CHRSCoherus Biosciences, Inc.Common0.80%$2M101.7K
33International Gaming TechnologiesCommon0.77%$2M100.0K
34ABAllianceBernstein Holding PL Unit Ltd.Common0.75%$2M49.0K
35ALXNAlexion Pharamaceuticals, Inc.Common0.75%$2M10.5K
36BCRXBioCryst Pharmaceuticals, Inc.Common0.74%$2M219.5K
37BioDelivery Sciences International, Inc.Common0.70%$2M370.2K
38Vapotherm, Inc.Common0.60%$1M49.0K
39uniQure N.V.Common0.57%$1M35.0K
40VKTXViking Therapeutics, Inc.Common0.56%$1M218.1K
41BACVerizon CommunicationsCommon0.45%$998,00017.0K
42CNSTConstellation Phamaceuticals, Inc.Common0.43%$950,00033.0K
43Verrica Pharmaceuticals, Inc.Common0.40%$881,00076.6K
44Cidara Therapeutics, Inc.Common0.38%$831,000415.3K
45RHPRyman Hospitality Ppty Inc.Common0.37%$813,00012.0K
46KMBKimberly Clark CorporationCommon0.37%$809,0006.0K
47JNJJohnson & JohnsonCommon0.36%$799,0005.1K
48MDLZMondelez Int'l Inc.Common0.34%$760,00013.0K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q3 2021$275M197Nov 12, 202113F-HRchanges · EDGAR ↗
Q2 2021$281M195Aug 13, 202113F-HRchanges · EDGAR ↗
Q1 2021$234M166May 13, 202113F-HRchanges · EDGAR ↗
Q4 2020$221M145Feb 12, 202113F-HRchanges · EDGAR ↗
Q3 2020$170M135Nov 13, 202013F-HRchanges · EDGAR ↗
Q2 2020$183M127Aug 12, 202013F-HRchanges · EDGAR ↗
Q1 2020$158M156May 13, 202013F-HRchanges · EDGAR ↗
Q4 2019$247M152Feb 14, 202013F-HRchanges · EDGAR ↗
Q3 2019$238M157Nov 12, 201913F-HRchanges · EDGAR ↗
Q2 2019$237M148Aug 12, 201913F-HRchanges · EDGAR ↗
Q1 2019$251M143May 13, 201913F-HRchanges · EDGAR ↗
Q4 2018$213M133Feb 12, 201913F-HRchanges · EDGAR ↗

Other Included Managers

This filing reports holdings on behalf of 1 additional manager.

  • DORSET MANAGEMENT CORP028-10281

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.